Abbott has received CE Mark for Xience Prime Everolimus Eluting Coronary Stent System, for the treatment of coronary artery disease.

The company plans to launch Xience Prime in a broad size matrix with lengths up to 38mm in Europe in the third quarter.

Xience Prime utilizes the same drug and proven biocompatible polymer as Xience V Everolimus Eluting Coronary Stent System. In addition, it offers a novel stent design and a modified delivery system, designed for greater flexibility and improved deliverability.

Xience Prime is currently under investigation in the US, and not available for sale.

Robert Hance, Senior Vice President of vascular, Abbott, said: Xience Prime leverages and will build upon the outstanding body of clinical evidence from the SPIRIT family of clinical trials. The modified design features of the stent and delivery system are intended to make it easier for physicians to deliver the stent to the treatment area.